Aclaris Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 07, 2023 at 07:00 am EDT
Share
Aclaris Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 1.87 million compared to USD 1.53 million a year ago. Net loss was USD 29.57 million compared to USD 20.53 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 0.31 a year ago.
For the six months, revenue was USD 4.4 million compared to USD 2.98 million a year ago. Net loss was USD 57.73 million compared to USD 39.32 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 0.62 a year ago.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.